BSECompany Update1d ago · 21 Jul 2026, 04:29 pm

Intimation of receipt of ANVISA approval for Biosimilar manufacturing facility of Curateq Biologics Private Limited, a wholly owned subsidiary of the Company.

Aurobindo Pharma Ltd · 524804

✦ AI Summary▲ PositiveRegulatory

Aurobindo Pharma Ltd has received ANVISA approval for its biosimilars manufacturing facility in Hyderabad, strengthening its capability to supply biosimilar products to the Brazilian and broader Latin American markets.

Analysis Scores

Earnings Impact6/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Aurobindo Pharma Ltd - 524804 - ANVISA Approval For Curateq Biologics'' Biosimilars Manufacturing Facility

Attachments (1)

📄

8d892748-47a1-48b5-b1ab-d08af5d389f6.pdf

pdf

Download →
View document text
July 21, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, Bandra (E), MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: ANVISA Approval for CuraTeQ Biologics' Biosimilars Manufacturing Facility Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that: CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has received approval from ANVISA (Agência Nacional de Vigilância Sanitária), the National Health Surveillance Agency of Brazil, for its biosimilars manufacturing facility in Hyderabad. The facility underwent a GMP inspection by ANVISA from May 11 to May 15, 2026, and the approval was granted following successful completion of the inspection for biological API and sterile products. The scope of the GMP inspection covered four biosimilar products and assessed the mammalian and microbial drug substance manufacturing facility, prefillable syringe and vial filling facility, packaging and labelling facility, QC testing and release laboratories. CuraTeQ’s drug substance and drug product GMP facility is already EMA (European Medicines Agency) and WHO certified and the ANVISA approval reaffirms CuraTeQ Biologics' commitment to global regulatory compliance and quality standards. The approval strengthens the Company's capability to supply biosimilar products to the Brazilian and broader Latin American markets. Please take the above information on record. Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com